Anifrolumab and low disease activity in people with systemic lupus erythematosus
Observes how well anifrolumab keeps lupus quiet with little steroid use.
Plain-language title generated from the registry record
Registry title: Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
Key facts
- Where
- Ancona, Bari, Brescia, Cona, Florence, Milan, Modena, Monserrato, Naples, Padova, Palermo, Pavia, Pisa, Roma, Rozzano, San Giovanni Rotondo, Torino, Trieste, Udine, and Verona, ItalySee the 22 sites
Where in Italy
- AOU Ospedali Riuniti di Ancona - Presidio TorretteAncona, ItalyTaking people
- Azienda Ospedaliero-Universitaria Policlinico di BariBari, ItalyNo longer taking part
- ASST Spedali Civili di BresciaBrescia, ItalyTaking people
- Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' AnnaCona, ItalyTaking people
- Azienda Ospedaliero-Universitaria CareggiFlorence, ItalyTaking people
- Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
- IRCCS Ospedale San RaffaeleMilan, ItalyNot yet recruiting
- Policlinico di Modena - AOU di ModenaModena, ItalyNot yet recruiting
- Azienda Ospedaliero-Universitaria di Cagliari Presidio di MonserratoMonserrato, ItalyTaking people
- Azienda Ospedaliera Universitaria Luigi VanvitelliNaples, ItalyNot yet recruiting
- Azienda Ospedaliera di PadovaPadova, ItalyNot yet recruiting
- Azienda Ospedaliera Universitaria Policlinico Paolo GiacconePalermo, ItalyTaking people
- Fondazione IRCCS Policlinico San MatteoPavia, ItalyTaking people
- Azienda Ospedaliero Universitaria Pisana - Ospedale Santa ChiaraPisa, ItalyNot yet recruiting
- Policlinico Tor VergataRoma, ItalyNot yet recruiting
- Policlinico Umberto I - Sapienza Università di RomaRoma, ItalyTaking people
- IRCCS Humanitas Research HospitalRozzano, ItalyTaking people
- IRCCS Casa Sollievo della SofferenzaSan Giovanni Rotondo, ItalyTaking people
- Azienda Ospedaliera Ordine Mauriziano Umberto ITorino, ItalyNot yet recruiting
- Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale di CattinaraTrieste, ItalyTaking people
- ASU Friuli Centrale - Ospedale Santa Maria della Misericordia di UdineUdine, ItalyTaking people
- AOUI Verona - Ospedale Borgo RomaVerona, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07330245
- Record updated
- 21 September 2026
- Original description
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5Read full original descriptionShow less
DAHLIA: Achievement of Low Level of Disease Activity With a Dose of Corticosteroids Less Than or Equal to 5 mg (LLDAS5): a Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
Inclusion: Provided informed consent to participate in the study; Aged 18 years or older; Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry; Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria.
Exclusion: Previous exposure to anifrolumab; Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy [mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus; Currently participating in any interventional clinical trial with an investigational product; Patients who are at LLDAS5 at the time of study entry; Inability to understand and sign the informed consent and to fill in patient questionnaires.